Dr. Kate Mangione discusses a study recently published in JAMA that looked at the effects of home-based physical therapy on elderly hip fracture patients.
Dr. Rebecca Craik, dean of the College of Health Sciences at Arcadia University discusses a study recently published in JAMA (Sept 2019) in which she was co-PI, that looked at the effects of home-based physical therapy on elderly hip fracture patients. The study shows that more rigorous physical therapy than what is usually offered can help return the patient to their “before” lifestyle.
Dr. Jerry Silver, Professor of Neurosciences at Case Western Reserve University’s School of Medicine and advisor to NervGen Pharma, discusses NervGen Pharma’s spinal cord regeneration technology. In animal studies an injectable peptide, developed by Dr. Silver and NervGen, allowed paralyzed rats to walk again. Phase 1 clinical trials are on the horizon in 2020.
Dr. Amit Kumar discusses the partnership with the Cleveland Clinic to develop an experimental vaccine for breast cancer.
John Termini recently presented his finding at the American Chemical Society annual meeting about how diabetes increases cancer risks.
The Optimized Patient: How to Prepare for, Survive, and Recover from Spine or Other Major Surgeries.
Michael Spigler discusses the American Kidney Fund‘s Beyond Bananas™ campaign supported by AstraZeneca. This campaign works as a resource for hyperkalemia patients while also raising awareness about high potassium and that it doesn’t just come from bananas and is a condition that must be closely monitored.
Lara Merriken founder of Larabar joins us to share how she stays fueled with real food while on the go, the importance of plant proteins and real food goodness.
Cellectis has pioneered the “off-the-shelf” approach to gene editing CAR T-cells to treat cancer and other genetic diseases. Dr. André Choulika discusses how this approach allows treatments to be produced by the thousands from healthy donor cells (versus the patient’s own cells), stored long-term, provided to hospitals around the world and given to any patient who is in medical need. Off-the-shelf gene editing marks the next transformative step in medicine, and Cellectis has the first U.S. clinical trials underway now.
CEO of Esperion, Tim Mayleben, speaks to the need for more therapies/options in the cholesterol-lowering space.